Investor Resources

DRUG (CSE)

Corporate Profile

We are a biotechnology company dedicated to developing next-generation therapeutics to improve the lives of patients with severe and life-altering brain diseases. Bright Minds’ broad portfolio of new chemical entities (NCEs) are positioned to treat a variety of pain indications, seizures, and neuropsychiatric disorders. By leveraging the extensive drug discovery experience of the Bright Minds team, we are creating a pipeline of best-in-class 5-HT (serotonin) medicines. Our patented, lead product candidates feature next generation characteristics, reducing unwanted side effects and maximizing therapeutic attributes. Bright Minds compounds are targeted therapies that allow for treatment of specific patient populations.

Partially Diluted Shares Outstanding (including in the money securities)

2,261,647*

*As of June 7th, 2021

Research Coverage

Firm Analyst Phone Email
Eight Capital Sepehr Manochehry, PhD +1 416-849-7801 smanochehry@viiicapital.com

Stock information

Stock Chart

Press Releases

02/14/2024

02/14/2024

02/14/2024

12/06/2023

08/08/2023

07/20/2023

07/11/2023

06/22/2023

04/19/2023

04/10/2023

02/27/2023

02/17/2023

02/08/2023

01/27/2023

01/09/2023

12/2/2022

11/28/2022

11/22/2022

09/13/2022

08/31/2022

08/30/2022

08/23/2022

08/22/2022

08/18/2022

06/27/2022

05/12/2022

05/02/2022

04/19/2022

03/14/2022

03/09/2022

01/04/2022

12/06/2021

11/30/2021

11/03/2021

10/07/2021

09/22/2021

08/09/2021

08/18/2021

06/16/2021

06/14/2021

06/11/2021

06/09/2021

05/17/2021

05/11/2021

05/04/2021

04/23/2021

04/23/2021

03/17/2021

03/15/2021

03/10/2021

03/03/2021

02/23/2021

02/22/2021

02/10/2021

02/05/2021

Bright Minds Biosciences Inc. - Committee Composition Table

Audit Committee Nominating and Corporate
Governance Committee
Compensation Committee Corporate Disclosure Committee
Nils Bottler Chair Chair Chair Chair
Jeremy Fryzuk Member Member Member Member
David Weiner Member Member Member Member

In the Media

11/24/2021

11/09/2021

08/26/2021

07/12/2021

07/07/2021

07/04/2021

06/30/2021

06/24/2021

02/02/2021

12/17/2020

12/16/2020

11/25/2020

08/07/2020

05/15/2020

08/12/2020

06/15/2020

Investor FAQs

Bright Minds was founded in 2017

DRUG trading on the Canadian Securities Exchange (CSE)

You can submit queries to Bright Minds’ investor relations department by contacting

ir@localhost

Partnering

If you are a pharmaceutical company interested in partnering with Bright Minds on one of our programs: partnering@brightmindsbio.com

Info

If you are a researcher interested in collaborating with Bright Minds or have a general question for the company: info@brightmindsbio.com

Press

Are you in publishing and looking for additional information?  write us at: press@brightmindsbio.com

Jobs

Interested in joining our team and helping to shape the future of brain health: jobs@brightmindsbio.com